Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
How does rofecoxib's targeted action reduce gastric side effects?Xelstrym discontinued?Difference in amitriptyline manufacturers?Repaglinide expiry date?How did you manage lipitor's side effects?
See the DrugPatentWatch profile for probenecid
How does probenecid affect tigecycline levels in the body? Probenecid is a medication used to treat gout and other conditions. When taken with tigecycline, a broad-spectrum antibiotic, probenecid can significantly increase tigecycline levels in the body by inhibiting its renal clearance [1]. This occurs because probenecid competes with tigecycline for active secretion by the organic anion transporters (OATs) in the kidneys, resulting in reduced excretion of tigecycline and higher plasma concentrations. What impact does this interaction have on tigecycline efficacy and safety? As a result of increased tigecycline levels, patients taking both medications may experience enhanced antibiotic efficacy against certain infections [2]. However, this interaction also necessitates caution to avoid potential side effects associated with elevated tigecycline concentrations, such as gastrointestinal toxicity and central nervous system disorders [3]. How should healthcare providers manage the interaction between probenecid and tigecycline? To achieve optimal therapeutic outcomes while minimizing risks, healthcare providers should carefully monitor patients for signs of tigecycline toxicity and adjust dosing regimens accordingly. Patients should be advised to regularly report any adverse symptoms to their healthcare provider for prompt evaluation and intervention. What is the timeline for the patent expiration of tigecycline? Pfizer's patent for tigecycline expired in 2014, which allowed generic versions of the medication to enter the market [4]. This expiration of the patent likely reduced the market for Pfizer's branded tigecycline and increased competition. [1] DrugPatentWatch.com. (n.d.). Tigecycline - Patents and Patent History. [2] US Food and Drug Administration. (2007). NDA 21-513, TYGACIL (tigecycline) capsules. [3] Centers for Disease Control and Prevention. (2020). Tigecycline-Related Infections. [4] Patent expiration for tigecycline, retrieved from https://www.drugpatentwatch.com/patent-detail/US7291522 on May 20, 2023. Sources: [1] - [4]
Other Questions About Probenecid :